Funding Resources
Funding Overview
Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
   Development
Contracts Management
Review Committees

Funding News

Program Areas

Research
Anticonvulsant Screening
   Program
Clinical Research
Counterterrorism
Epilepsy Research Web
Neural Interfaces Program
NIH Roadmap Research
Parkinson's Web
Resources for Scientists
Stem Cell Research
Translational Research
Traumatic Brain Injury
   (TBI) Research
Technology Transfer
   Office

Contact Us
My Privacy

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

  Print-friendly version

   Email this page

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), the National Institute on Deafness and Other Communication Disorders (NIDCD), the National Institute of Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), the National Institute on Aging (NIA), and the National Institute of Environmental Health Sciences (NIEHS) invite Small Business Innovation Research (SBIR) grant applications to develop novel radioligands for positron emission tomography (PET) and single photon emission tomography (SPECT) imaging in human brain.*

The use of radiotracers for imaging molecular events in preclinical and clinical studies is essential for understanding the biological basis of normal brain function and the pathophysiology of brain disorders. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials.

This initiative is intended to stimulate the development of radioligands for molecular targets that are of broad interest to the scientific community. Use of these radioligands is expected to accelerate research on identifying and characterizing the neural circuits and pathways implicated in the pathophysiology of brain disorders, and to facilitate the identification of new therapeutic targets and the development of new compounds as potential therapeutic agents. Molecular targets for which radioligands are needed include receptors, transporters, enzymes, and intracellular targets.

For more information, potential applicants should contact Technology Development Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2139, Bethesda, MD 20892; telephone: 301-496-1779; fax: 301-402-1501; e-mail: funding@ninds.nih.gov.

*For a more detailed description of this program announcement, please visit the NIH web site at: http://grants.nih.gov/grants/guide/pa-files/PA-02-028.html.

---

This content has been adapted from the original NINDS Notes publication. For the most up-to-date funding information, please visit the Funding Opportunities section of the NINDS web site.  For the most recent information on NINDS studies, please visit the NINDS Patient Recruitment web site.